VERAXA Biotech AG (NASDAQ: VRXA) has taken a significant step in advancing its proprietary BiTAC-TCE platform after receiving Scientific Advice from Germany's Paul-Ehrlich-Institute (PEI), providing regulatory feedback on the biological rationale and proposed non-clinical development strategy for its lead therapeutic program. The announcement, released on July 20, marks progress as the company prepares its most advanced BiTAC-TCE candidate for future clinical development (https://ibn.fm/zBiDU).
The regulatory feedback supports the company's proposed development strategy, offering early guidance on biological rationale, safety assessments, and non-clinical development plan. VERAXA believes this advice helps reduce development uncertainty by providing greater clarity before advancing toward clinical studies. The lead BiTAC-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats. The latest regulatory milestone follows continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer.
Scientific Advice procedures allow drug developers to consult with regulatory experts before clinical trials begin, helping companies align their development strategies with regulatory expectations regarding safety, tolerability, and efficacy. The PEI's positive feedback is a crucial step for VERAXA, as it validates the company's approach and may streamline the path to clinical trials.
The company's BiTAC-TCE platform is designed to engage T cells to attack cancer cells, a mechanism that has shown promise in preclinical models. With the regulatory feedback in hand, VERAXA is well-positioned to move forward with its lead candidate, potentially bringing a novel therapy to patients in need.
Investors and stakeholders can find the latest news and updates relating to VRXA in the company's newsroom at https://ibn.fm/VRXA.
